Hyperkalemia
Part of NephTimes
Advertisement
The American Kidney Fund introduced guidelines to help patients with chronic kidney disease manage and treat hyperkalemia.
Researchers studied the efficacy of a community pharmacist-led nutritional intervention for outpatients with CKD.
Could SZC use allow for quick and safe initiation and titration of MRAs and long-term optimal dosing for patients with HRrEF?
Authors described the case of a patient with BRASH syndrome-induced atrial fibrillation with a slow ventricular response.
What influence does hyperkalemia have on disease severity and mortality risk among patients admitted to the emergency room?
Researchers studied how race, ethnicity, and other demographic factors relate to the risk of recurrent hyperkalemia.
Transplant recipients often present with characteristics that may be associated with hyperkalemic renal tubular acidosis.
Pooja Desai discussed a study examining short- vs long-term results of SZC therapy on hyperkalemia-related hospitalization.
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
Potassium adsorbents lower serum potassium levels but their effects on mortality and rehospitalization rates were unclear.
Researchers sought to determine the palatability of SZC, patiromer, and S/CPS in patients with CKD and hyperkalemia.
Experts developed consensus statements for management of hyperkalemia in the Asia–Pacific region.
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes.
When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC.
Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias.
There are few data available on the adverse effect of hyperkalemia on progression of chronic kidney disease (CKD).
Patients with hyperkalemia treated with SCZ have a higher rate of continuation of RAAS inhibition.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.